New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 2, 2014
08:37 EDTBIOCBiocept expands breast cancer offering
Biocept announced the launch of its estrogen receptor status testing on CTCs that will be performed at the Company's CLIA-certified and CAP-accredited laboratory. The launch of ER status testing, in conjunction with the company's HER2 receptor status test, will offer health care providers an additional testing option when a tumor biopsy is unavailable or unsafe. For patients with recurring or newly diagnosed metastatic breast cancer, accurate identification of hormone and HER2 receptors status plays a major role in treatment outcomes. The company said, "Our validation study for hormone status provided significant insights into hormone status as it relates to primary and metastatic breast cancers. We were able to correlate both concordance and discordance of primary biopsy tissue and metastatic biopsy tissue with the CTC status of estrogen receptors."
News For BIOC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 14, 2015
09:20 EDTBIOCOn The Fly: Pre-market Movers
HIGHER: Natural Health Trends Corp. (NHTC), up 16.2% following second quarter guidance... Transgenomic (TBIO), up 14% after launching genetic test for Leukodystrophy diagnosis... Biocept (BIOC), up 12.4% after launching diagnostic assay for BRAF mutations in melanoma patients... Micron (MU), up 13.1% after WSJ reports that Tsinghua made $23B acquisition offer... SanDisk (SNDK) and AMD (AMD) are up 3.8% and 3.1%, respectively, following reports of Tsinghua offer to Micron... GoPro (GPRO), up 3.2% after being upgraded to Overweight from Equal Weight at Barclays. DOWN AFTER EARNINGS: Wells Fargo (WFC), down 1%... JPMorgan (JPM), down fractionally. ALSO LOWER: Vince Holding (VNCE), down 16.3% after being downgraded to Market Perform from Outperform at William Blair... Tonix Pharmaceuticals (TNXP), down 8.3% after 2.3M share Spot Secondary priced at $7.50... Spirit Airlines (SAVE), down 7.4% after pricing pressure leads to reduced fiscal 2015 margin view... Orbitz Worldwide (OWW), down 2.8% after being downgraded to Sell from Neutral at UBS.
07:03 EDTBIOCBiocept launches diagnostic assay for BRAF mutations in melanoma patients
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use